BR112017013009A2 - formulação de vírus herpes simplex congelada estável - Google Patents

formulação de vírus herpes simplex congelada estável

Info

Publication number
BR112017013009A2
BR112017013009A2 BR112017013009A BR112017013009A BR112017013009A2 BR 112017013009 A2 BR112017013009 A2 BR 112017013009A2 BR 112017013009 A BR112017013009 A BR 112017013009A BR 112017013009 A BR112017013009 A BR 112017013009A BR 112017013009 A2 BR112017013009 A2 BR 112017013009A2
Authority
BR
Brazil
Prior art keywords
herpes simplex
simplex virus
virus formulation
stable frozen
frozen
Prior art date
Application number
BR112017013009A
Other languages
English (en)
Inventor
Arthur Kerwin Bruce
Claudia SISKA Christine
R Litowski Jennifer
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR112017013009A2 publication Critical patent/BR112017013009A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112017013009A 2014-12-18 2015-12-15 formulação de vírus herpes simplex congelada estável BR112017013009A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462093663P 2014-12-18 2014-12-18
PCT/US2015/065858 WO2016100364A1 (en) 2014-12-18 2015-12-15 Stable frozen herpes simplex virus formulation

Publications (1)

Publication Number Publication Date
BR112017013009A2 true BR112017013009A2 (pt) 2018-06-26

Family

ID=55229814

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013009A BR112017013009A2 (pt) 2014-12-18 2015-12-15 formulação de vírus herpes simplex congelada estável

Country Status (19)

Country Link
US (2) US20170360857A1 (pt)
EP (1) EP3234114B9 (pt)
JP (2) JP6975041B2 (pt)
KR (2) KR20230107375A (pt)
CN (1) CN107580626A (pt)
AU (2) AU2015362687B2 (pt)
BR (1) BR112017013009A2 (pt)
CA (1) CA2971201A1 (pt)
CL (1) CL2017001563A1 (pt)
CO (1) CO2017007086A2 (pt)
EA (1) EA201791382A1 (pt)
ES (1) ES2948037T3 (pt)
HK (1) HK1245823A1 (pt)
IL (3) IL300202B2 (pt)
MA (1) MA40948A (pt)
MX (2) MX2017008013A (pt)
SG (1) SG11201704975SA (pt)
WO (1) WO2016100364A1 (pt)
ZA (1) ZA201704695B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3217993A1 (en) * 2015-07-20 2017-09-20 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
WO2019213509A1 (en) * 2018-05-03 2019-11-07 Rutgers, The State University Of New Jersey Compositions and methods for treating cancer
CN109161562A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭肝癌细胞的新型溶瘤病毒及其构建方法
EP3902529A1 (en) * 2018-12-27 2021-11-03 Amgen Inc. Lyophilized virus formulations
WO2022006745A1 (en) * 2020-07-07 2022-01-13 Oriengene Biotechnology Ltd Guide rna for hsv-1 gene editing and method thereof
CN116421734A (zh) * 2021-12-30 2023-07-14 深圳复诺健生物科技有限公司 适用于溶瘤病毒的冻干保护剂及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63307827A (ja) * 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1141338A4 (en) 1998-12-31 2002-09-25 Arch Dev Corp RECOMBINANT HERPES SIMPLEX VIRUS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES
WO2000054795A1 (en) 1999-03-15 2000-09-21 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1381280B1 (en) 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
EP1494613A4 (en) 2002-03-27 2008-06-18 Baylor College Medicine EFFECTIVE ONCOLYTIC HERPES SIMPLEX VIRUS FOR CANCER THERAPY
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US20060141483A1 (en) 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH 1 (MP-1) AND METHODS FOR TREATING CANCER USING ANTI-MP-1 ANTIBODIES ALONE OR ASSOCIATED WITH OTHER IMMUNOTHERAPIES
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CN101230335B (zh) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN101230334B (zh) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
EP2144998B1 (en) * 2007-04-06 2017-01-04 Takeda Vaccines, Inc. Methods and compositions for live attenuated viruses
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
HRP20240240T1 (hr) 2008-12-09 2024-04-26 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
US20130202639A1 (en) * 2010-03-25 2013-08-08 Konstantin G. Kousoulas Synthetic Herpes Simplex Viruses for Treatment of Cancers
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN101926990A (zh) * 2010-09-21 2010-12-29 中山大学 肿大细胞病毒vsocs基因缺失减毒活疫苗及其制备方法和应用
US20130028882A1 (en) 2011-07-07 2013-01-31 Humanitas Technology, LLC Antiviral compositions and methods of their use
EP2802649B1 (en) 2012-01-09 2017-08-09 Sanofi Pasteur Biologics, LLC Purification of herpes virus
WO2013177172A2 (en) 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
EP3381942B1 (en) * 2012-08-30 2021-04-14 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor

Also Published As

Publication number Publication date
AU2015362687A1 (en) 2017-07-06
IL300202B1 (en) 2023-12-01
CA2971201A1 (en) 2016-06-23
IL300202B2 (en) 2024-04-01
IL252942A0 (en) 2017-08-31
JP2021072795A (ja) 2021-05-13
CN107580626A (zh) 2018-01-12
US20210052680A1 (en) 2021-02-25
ES2948037T3 (es) 2023-08-30
MX2023012564A (es) 2023-11-08
KR20170095270A (ko) 2017-08-22
IL300202A (en) 2023-03-01
AU2015362687B2 (en) 2021-12-09
IL308119A (en) 2023-12-01
CL2017001563A1 (es) 2018-01-26
EP3234114B9 (en) 2023-06-14
JP6975041B2 (ja) 2021-12-01
WO2016100364A1 (en) 2016-06-23
SG11201704975SA (en) 2017-07-28
EA201791382A1 (ru) 2017-10-31
MX2017008013A (es) 2018-03-06
CO2017007086A2 (es) 2017-10-10
KR102549746B1 (ko) 2023-07-03
EP3234114A1 (en) 2017-10-25
JP2018502078A (ja) 2018-01-25
US20170360857A1 (en) 2017-12-21
HK1245823A1 (zh) 2018-08-31
MA40948A (fr) 2017-10-25
KR20230107375A (ko) 2023-07-14
AU2022201523A1 (en) 2022-03-24
EP3234114B1 (en) 2023-04-12
ZA201704695B (en) 2023-12-20

Similar Documents

Publication Publication Date Title
FIC20230006I1 (fi) Vutrisiraani
IL258833A (en) Make simple shingles virus
HK1256195A1 (zh) 穩定的抗ifnar1配製品
DK3218519T3 (da) Multipass-sekvensering
IL250363A0 (en) Stable formulation of anti-il-4r-alpha antibody
FR3019458B1 (fr) Refracteur
CL2014003612S1 (es) Peine para aparato de aseo
HK1245823A1 (zh) 穩定的冷凍單純性疱疹病毒製劑
CL2015001019S1 (es) Ampolleta
DK3129006T3 (da) Immunsupprimerende formulering
DK3212237T3 (da) Methotrexatformulering
DK3205661T3 (da) Hsp70-afledt immunitetsinducerende peptid
DE112015003841A5 (de) Di- und triphosphat-propharmaka
DK3372589T3 (da) Pyrimidinderivat
GB201520345D0 (en) Herpes simplex viruses
ITUB20152286A1 (it) Composizione anti herpes
BR112016017925A2 (pt) Formulação de colagem estabilizada
CL2016002705A1 (es) Formulación agroquímica
DK3233839T3 (da) Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer
BR112016027580A2 (pt) Formulação de ceritinib
DK3394346T3 (da) Adapter
ITUA20163470A1 (it) Formulazione antiappannante
TR201503831A2 (tr) Antimipertansif kombinasyon formülasyonları
DK3193856T3 (da) Formulering
FR3040250B3 (fr) Adaptateur

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]